Recombinant Dna Technology Market is estimated to be valued at USD 172.94 Bn in 2024 and is expected to exhibit a CAGR of 9.6% over the forecast period (2024-2031). The global recombinant DNA technology market is witnessing high growth owing to the increasing research focusing on the development of gene and cell therapies. Recombinant DNA technology helps in modifying the genome of living organisms for various applications in healthcare, agriculture, and research.
Market Dynamics:
The recombinant DNA technology market is primarily driven by increasing research and development activities for developing novel therapies. Significant funding from both private and public organizations is encouraging research for developing new treatments for chronic diseases using recombinant DNA technology. For instance, the National Institutes of Health provided a funding of over USD 42 billion in 2021 for various R&D projects utilizing recombinant DNA technology. The emergence of new technologies such as Clustered regularly interspaced short palindromic repeats (CRISPR) is also fueling the market growth. CRISPR has emerged as a breakthrough technology for precisely editing genes and holds immense potential in disease treatment. With ongoing advancements, CRISPR is becoming more efficient and cost-effective, further expanding its applications. The development of CRISPR-based therapies and their successful clinical trials will propel the demand for recombinant DNA technology.
Growing demand for biopharmaceuticals drives growth in the recombinant DNA technology market
The growing demand for biopharmaceuticals such as insulin, human growth hormone, and monoclonal antibodies is a major driver for the recombinant DNA technology market. Biopharmaceuticals developed using recombinant DNA technology are playing a more important role in the treatment of various diseases. Their demand has been increasing significantly due to the advantages they offer over conventional small-molecule drugs such as higher target specificity, lower toxicity, and better efficacy. According to research, the global biopharmaceutical market was valued at over US$ 250 billion in 2020 and is projected to grow at a CAGR of around 9% during 2021-2027.
Increased focus on research and development for new drug development acts as a key growth catalyzer
The increasing focus of pharmaceutical and biotech companies on R&D activities for new drug development using recombinant DNA technology is another major driver for this market. Major key market player are extensively investing in R&D to develop innovative biologics and biosimilars for the treatment of various chronic and complex diseases like cancer, diabetes, cardiovascular diseases, etc. Recombinant DNA technology allows manufacturing of complex therapeutic proteins with high purity and consistency for clinical use, which traditional chemical synthesis cannot achieve. The growing pipeline of recombinant proteins/drugs under development and increasing clinical trials will augment the demand for recombinant DNA technologies in research laboratories as well as manufacturing facilities.
High costs associated with research and development and manufacturing restrain the market growth
Full-scale surgical robotic systems can cost over US$ 1-2 million to purchase initially. There are also added costs involved in multi-year service contracts, training of medical staff, and sterile drapes for each procedure. The high capital expense and additional operational expenditures pose a major restraint, especially for public hospitals and small healthcare facilities in developing regions. Limited budgets for surgical equipment upgrades deter many hospitals from investing in robotic technologies. With robots accounting for only a small fraction of total surgeries presently, their high prices fail to generate worthwhile returns on investment for hospitals. This cost-related barrier continues to impede faster adoption rates and market expansion globally.
Strict regulatory framework hinders the progress of research
Complying with the strict regulations for the approval and commercialization of products developed using recombinant DNA technologies is another major restraint. Regulatory bodies like the U.S. Food and Drug Administration (FDA) have very stringent guidelines for the production, testing, and distribution of recombinant therapeutics to ensure product safety and effectiveness. Obtaining regulatory approvals is a lengthy, expensive process which requires extensive documentation and clinical data. Moreover, any changes to the manufacturing process require additional approvals and compliance. The complex regulatory framework directed towards biosafety and biosecurity hinders fast-paced research progress. It also limits the number of market players, especially smaller ventures with limited capabilities and resources. This acts as a roadblock in the smooth growth of the recombinant DNA technology industry.
Increasing demand for personalized medicine opens new avenues
One of the key opportunities for the recombinant DNA technology market lies in the increasing demand for personalized medicine. Recombinant proteins allow developing customized therapeutics for specific patient populations and designing tailored treatments. Companies are using technologies like DNA sequencing, genome engineering tools like CRISPR to develop novel diagnostic tests for precision medicine. Researchers are creating recombinant antibodies, cell and gene therapies customized for an individual's genetic profile to treat cancer and other complex diseases. The scope of personalized medicine is expanding rapidly and driving increased research into recombinant platforms for companion diagnostics as well as targeted therapies.
*Link: https://www.coherentmarketinsights.com/market-insight/recombinant-dna-technology-market-893
Key Development
- On January 24, 2024, Core Biogenesis, a biotechnology company, and Nucleus Biologics, a provider of custom cell-growth media, tools, and technologies for cell and gene therapy, announced a collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins
- In March 2022, ProteoGenix, a contract research organization specialized in biologics discovery and bioproduction, announced the launch of its XtenCHO Transient Expression System. The new CHO host aims to simplify recombinant protein production and accelerate early phase drug screening.
- In January 2022, Thermo Fisher Scientific Inc., a global biotechnology company, announced the acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. PeproTech's recombinant proteins portfolio complements Thermo Fisher Scientific Inc. cell culture media products and will enable Thermo Fisher Scientific Inc. to provide customers significant benefits through an integrated offering.
- In June 2020, Lonza, a global healthcare company, announced that it had expanded its cell culture media portfolio with the addition of the GSv9 Media and Feeds, providing a fully integrated solution specifically designed to optimize recombinant protein production using Lonza’s GS Gene Expression System
Key Players: Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi , Pfizer, Inc., Amgen, Inc., Merck & Co., Inc., Profacgen, Monsanto Company, Genentech Inc., Eli Lilly and Company, Janssen Pharmaceuticals Inc., GSK plc., Jiangsu Recbio Technology Co., Ltd., New England Biolabs, GenScript, Lonza, and ProteoGenix
